AUS
NZ
UK
CA
USA
IND
Highlights
- Wellington Management Group LLP recently acquired 465,672 shares of Erasca, Inc., indicating growing institutional interest.
- Erasca's market performance saw a notable increase, trading up 16.4% and achieving a market capitalization of $351.25 million.
- With a consensus "Buy" rating and an average target price of $4.83, Erasca has been attracting positive analyst attention.
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company, has garnered significant attention recently due to a surge in institutional investments. Wellington Management Group LLP entered the scene by acquiring a new stake comprising 465,672 shares, valued at approximately $1,169,000 during the fourth quarter. This acquisition contributed to Wellington Management Group LLP owning about 0.16% of the company's shares by the end of the reporting period.
In addition to Wellington, other institutional investors have been actively adjusting their positions in Erasca. The Manufacturers Life Insurance Company increased its holdings by 41.4% in the third quarter, now owning 67,661 shares worth $185,000. FMR LLC expanded its stake by 32.8% to 306,129 shares, valued at $836,000. UBS Asset Management Americas LLC acquired a new position in the company, which was valued at about $994,000 during the same period. Furthermore, State Street Corp bolstered its position by an impressive 145.2% to hold 6,027,620 shares, valuing approximately $16,455,000. Barclays PLC also grew its stake by a substantial 627.5%, owning 343,930 shares worth $939,000. At present, 67.78% of Erasca's stock is in the hands of institutional investors and hedge funds.
Erasca's market performance has been notable, with shares opening at $1.24 and posting an increase of 16.4%. Despite a one-year low of $1.01, the stock has a high of $3.45, resulting in a current market capitalization of $351.25 million. Analysts' forecasts are optimistic, with expected earnings per share of -0.73 for the current year. The company reported a quarterly earnings of ($0.11) per share, slightly surpassing consensus estimates of ($0.12). This compares favorably with the previous year's same-quarter earnings of ($0.20) per share.
Further underlining Erasca's momentum, the company has received ratings upgrades from several financial analysts. Bank of America raised its rating from “neutral” to “buy,” setting a target price of $5.00. Similarly, The Goldman Sachs Group adjusted its price objective from $3.50 to $3.00 while maintaining a “buy” rating. Raymond James initiated coverage with an “outperform” rating and a target price of $5.00. HC Wainwright and Morgan Stanley reiterated “buy” and “overweight” ratings, with target prices set at $6.00 and $4.00, respectively. According to MarketBeat.com, the consensus rating is “Buy,” with an average target price of $4.83.
In terms of corporate focus, Erasca is dedicated to developing therapies for RAS/MAPK pathway-driven cancers. Their lead product, Naporafenib, is currently in a Phase 1b trial targeting RAS Q16X solid tumors. The company plans to initiate a pivotal Phase 3 trial for NRASm melanoma patients, signaling ongoing advancements in its clinical-stage developments.
